Payment overview · 2025
General Payments
$251.93
14 reported records · 10 companies
Healthcare provider profile · identity verified
Charles R Ducombs, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HAMMOND, LA · NPI 1891765954
Verified facts
What the public records show
CMS Open Payments records show Charles R Ducombs, M.D. received $251.93 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.45 | 35.1% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.16 | 13.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.82 | 8.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.26 | 8.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.17 | 8.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.43 | 6.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.19 | 6.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.99 | 5.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.05 | 4.4% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $8.41 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $251.93 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $65.46 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.39 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $34.16 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $8.41 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $8.41 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $8.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 77 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 340 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
77 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
220 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
340 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
216 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 1165 | 289 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1159 | 300 |
| Levothyroxine Sodium | Levothyroxine Sodium | 684 | 164 |
| Gabapentin | Gabapentin | 586 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 572 | 169 |
| Losartan Potassium | Losartan Potassium | 554 | 147 |
| Metoprolol Succinate | Metoprolol Succinate | 517 | 120 |
| Alprazolam | Alprazolam | 463 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 353 | 107 |
| Furosemide | Furosemide | 349 | 110 |
| Trazodone Hcl | Trazodone Hcl | 347 | 81 |
| Mounjaro | Tirzepatide | 340 | 57 |
| Potassium Chloride | Potassium Chloride | 337 | 89 |
| Montelukast Sodium | Montelukast Sodium | 277 | 77 |
| Irbesartan | Irbesartan | 271 | 62 |
| Meloxicam | Meloxicam | 265 | 77 |
| Felodipine Er | Felodipine | 251 | 50 |
| Allopurinol | Allopurinol | 249 | 64 |
| Prednisone | Prednisone | 233 | 171 |
| Escitalopram Oxalate | Escitalopram Oxalate | 229 | 57 |
| Eliquis | Apixaban | 220 | 41 |
| Ozempic | Semaglutide | 216 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 55 |
| Ezetimibe | Ezetimibe | 200 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 70 |
| Metformin Hcl Er | Metformin Hcl | 183 | 52 |
| Simvastatin | Simvastatin | 171 | 47 |
| Bupropion Xl | Bupropion Hcl | 168 | 41 |
| Tramadol Hcl | Tramadol Hcl | 164 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 150 | 44 |
| Sertraline Hcl | Sertraline Hcl | 150 | 39 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 148 | 33 |
| Atenolol | Atenolol | 145 | 37 |
| Omeprazole | Omeprazole | 143 | 40 |
| Januvia | Sitagliptin Phosphate | 140 | 27 |
| Ondansetron Odt | Ondansetron | 140 | 58 |
| Nifedipine Er | Nifedipine | 137 | 28 |
| Carvedilol | Carvedilol | 130 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 126 | 49 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 124 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 120 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 29 |
| Metformin Hcl | Metformin Hcl | 120 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 44 |
| Memantine Hcl | Memantine Hcl | 115 | 28 |
| Jardiance | Empagliflozin | 114 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 33 |
| Clonazepam | Clonazepam | 110 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 23 |
| Lorazepam | Lorazepam | 99 | 23 |
| Celecoxib | Celecoxib | 98 | 29 |
| Glimepiride | Glimepiride | 97 | 28 |
| Cefdinir | Cefdinir | 95 | 80 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | 17 |
| Buspirone Hcl | Buspirone Hcl | 85 | 31 |
| Linzess | Linaclotide | 77 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 23 |
| Trulicity | Dulaglutide | 72 | 14 |
| Diazepam | Diazepam | 70 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 23 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 66 | 29 |
| Donepezil Hcl | Donepezil Hcl | 66 | 16 |
| Lisinopril | Lisinopril | 66 | 24 |
| Chlorthalidone | Chlorthalidone | 65 | 17 |
| Famotidine | Famotidine | 65 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 52 |
| Synthroid | Levothyroxine Sodium | 64 | 12 |
| Valsartan | Valsartan | 62 | 15 |
| Entresto | Sacubitril/Valsartan | 61 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 61 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 59 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 55 | 27 |
| Cephalexin | Cephalexin | 54 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 20 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 52 | 11 |
| Meclizine Hcl | Meclizine Hcl | 52 | 25 |
| Topiramate | Topiramate | 51 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 14 |
| Alendronate Sodium | Alendronate Sodium | 49 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 17 |
| Primidone | Primidone | 49 | 11 |
| Hydrocortisone | Hydrocortisone | 48 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 37 |
| Spiriva Handihaler | Tiotropium Bromide | 46 | 12 |
| Methylprednisolone | Methylprednisolone | 45 | 41 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 15 |
| Dutasteride | Dutasteride | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 44 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Estradiol | Estradiol | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 40 | 13 |
| Ramipril | Ramipril | 40 | 11 |
| Digoxin | Digoxin | 39 | suppressed |
| Mupirocin | Mupirocin | 39 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 32 |
| Mirtazapine | Mirtazapine | 37 | 11 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | 11 |
| Spironolactone | Spironolactone | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Nystatin | Nystatin | 33 | 19 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Baclofen | Baclofen | 28 | 15 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 16 |
| Acyclovir | Acyclovir | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $251.93 · 14 records | ABBVIE INC. | AREXVY, CAMZYOS, CREON, EVENITY, LINZESS, MOUNJARO, SHINGRIX, STRENSIQ, VOQUEZNA, XIFAXAN, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error